Inhibition of membrane-associated viral replication

1. A method for inhibiting production of a virus belonging to the Flaviviridae family comprising contacting a mammalian cell infected by said virus with an effective amount of a 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula ##STR2## wherein R.sup.1 is selected from the group consisting of H; alkyl; alkenyl; alkoxy; acyl; aryl; aralkyl; aroyl; aralkoxy; and heterocyclic groups; and R.sup.3, R.sup.4 and R.sup.5 are the same or different and are selected from the group consisting of H; acyl; and aroyl groups; and R.sup.6 is hydrogen, or an alkyl, alkenyl, acyl, aroyl or aralkyl group; wherein said acyl, alkyl and alkenyl groups have from 1 to 14 carbon atoms and are linear or branched, substituted or unsubstituted, and said alkenyl groups have from 1 to 6 double bonds; and wherein said aryl groups and heterocyclic groups have from 7 to 14 carbon atoms and are optionally substituted by halogen, hydroxy, C.sub.1-10 alkyl; C.sub.1-10 alkylene; C.sub.1-10 acyl or C.sub.1-10 alkoxy; and enantiomers and stereoisomers of said compound and physiologically acceptable salts or solvates of said compound, enantiomer or stereoisomer. 2. A method according to claim 1 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl group; wherein said alkyl group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 3. A method according to claim 1 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkoxy group, wherein said alkoxy group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. ##STR3## 4. A method according to claim 1 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl, alkoxy, aralyl, aralkyl, or aralkoxy. 5. A method according to claim 1 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with a nonyl group; wherein said nonyl group is linear or branched, and substituted or unsubstituted. ##STR4## 6. A method according to any one of claims 1-5 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.3, R.sup.4, R.sup.5 and R.sup.6 by a hydrogen group. 7. A method according to any one of claims 2-6 wherein at least one of R.sup.3, R.sup.4 and R.sup.5 is an acyl group. 8. A method according to claim 1 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, stereoisomer, or physiologically acceptable salt or solvate of said compound, enantiomer, or stereoisomer is administered to a mammal. 9. A method according to claim 8 wherein the 1,5-dideoxy-1,5-imino-D-gucitol derivative compound, enantiomer, stereoisomer, or physiologically acceptable salt or solvate of said compound, enantiomer, or stereoisomer is administered to a human. 10. A method according to claim 1 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, stereoisomer, or physiologically acceptable salt or solvate of said compound, enantiomer, or stereoisomer is administered to said mammalian cell in vivo. 11. A method according to claim 1 wherein said virus is a flavivirus. 12. A method according to claim 11 wherein the flavivirus is selected from the group consisting of yellow fever virus, dengue viruses 1-4, Japanese encephalitis virus, Murray Valley encephalitis, Rocio virus, West Nile fever virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Louping ill virus, Powassan virus, Omsk hemorrhagic fever virus and Kyasanur forest disease virus. 13. A method according to claim 11 wherein the flavivirus is selected from the group consisting of yellow fever virus, a dengue virus and Japanese encephalitis virus. 14. A method according to claim 1 wherein said virus is a pestivirus. 15. A method for inhibiting production of a virus belonging to the Flaviviridae family comprising contacting a mammalian cell infected by said virus with an effective amount of a 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula ##STR5## wherein R.sup.1 is selected from the group consisting of H, alkyl, alkenyl, alkoxy, acyl, aryl, aralkyl, aroyl, aralkoxy, and heterocyclic groups; and wherein said acyl, alkyl and alkenyl groups have from 7 to 14 carbon atoms and are linear or branched, substituted or unsubstituted; said alkenyl groups have from 1 to 6 double bonds; and said aryl groups and heterocyclic groups have from 7 to 14 carbon atoms and are optionally substituted by halogen, hydroxy, C.sub.1-10 alkyl; C.sub.1-10 alkylene; C.sub.1-10 acyl or C.sub.1-10 alkoxy; and enantiomers and stereoisomers of said compound and physiologically acceptable salts or solvates of said compound, enantiomer or stereoisomer. 16. A method according to claim 15 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl group; wherein said alkyl group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 17. dA method according to claim 15 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkoxy group; wherein said alkoxy group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 18. A method according to claim 15 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl, alkoxy, aralkyl, or aralkoxy group. 19. A method according to claim 15 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with a nonyl group; wherein said nonyl group is linear or branched, and substituted or unsubstituted. 20. A method according to claim 15 wherein the 1,5-dideoxy-1,5-imino-D-glucitol compound, enantiomer, stereoisomer, or physiologically acceptable salt or solvate of said compound, enantiomer, or stereoisomer is administered to a human in vivo. 21. A method according to claim 15 wherein said virus is a flavivirus. 22. A method according to claim 21 wherein the flavivirus is selected from the group consisting of yellow fever virus, dengue viruses 1-4, Japanese encephalitis virus, Murray Valley encephalitis, Rocio virus, West Nile fever virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Louping ill virus, Powassan virus, Omsk hemorrhagic fever virus and Kyasanur forest disease virus. 23. A method according to claim 21 wherein the flavivirus is selected from the group consisting of yellow fever virus, a dengue virus and Japanese encephalitis virus. 24. A method according to claim 15 wherein said virus is a pestivirus. 25. A method for inhibiting production of a Hepatitis C virus comprising contacting a mammalian cell infected by said Hepatitis C virus with an effective amount of a 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula ##STR6## wherein R.sup.1 is selected from the group consisting of H; alkyl; alkenyl; alkoxy; acyl; aryl; aralkyl; aroyl; aralkoxy; and heterocyclic groups; and R.sup.3, R.sup.4 and R.sup.5 are the same or different and are selected from the group consisting of H; acyl; and aroyl groups; and R.sup.6 is hydrogen, or an alkyl, alkenyl, acyl, aroyl or aralkyl group; wherein said acyl, alkyl and alkenyl groups have from 1 to 14 carbon atoms and are linear or branched, substituted or unsubstituted, and said alkenyl groups have from 1 to 6 double bonds; and wherein said aryl groups and heterocyclic groups have from 7 to 14 carbon atoms and are optionally substituted by halogen, hydroxy, C.sub.1-10 alkyl; C.sub.1-10 alkylene; C.sub.1-10 acyl or C.sub.1-10 alkoxy; and enantiomers and stereoisomers of said compound and physiologically acceptable salts or solvates of said compound, enantiomer or stereoisomer. 26. A method according to claim 25 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl group; wherein said alkyl group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 27. A method according to claim 25 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkoxy group; wherein said alkoxy group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 28. A method according to claim 25 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl, alkoxy, aralyl, aralkyl, or aralkoxy. 29. A method according to claim 25 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with a nonyl group; wherein said nonyl group is linear or branched, and substituted or unsubstituted. 30. A method according to any one of claims 25-29 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.3, R.sup.4, R.sup.5 and R.sup.6 by a hydrogen group. 31. A method according to any one of claims 25-29 wherein at least one of R.sup.3, R.sup.4 and R.sup.5 is an acyl group. 32. A method according to claim 25 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, stereoisomer, or physiologically acceptable salt or solvate of said compound, enantiomer, or stereoisomer is administered to a human. 33. A method for inhibiting production of a Hepatitis C virus comprising contacting a mammalian cell infected by said Hepatitis C virus with an effective amount of a 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula ##STR7## wherein R.sup.1 is selected from the group consisting of H, alkyl, alkenyl, alkoxy, acyl, aryl, aralkyl, aroyl, aralkoxy, and heterocyclic groups; and wherein said acyl, alkyl and alkenyl groups have from 7 to 14 carbon atoms and are linear or branched, substituted or unsubstituted; said alkenyl groups have from 1 to 6 double bonds; and said aryl groups and heterocyclic groups have from 7 to 14 carbon atoms and are optionally substituted by halogen, hydroxy, C.sub.1-10 alkyl; C.sub.1-10 alkylene; C.sub.1-10 acyl or C.sub.1-10 alkoxy; and enantiomers and stereoisomers of said compound and physiologically acceptable salts or solvates of said compound, enantiomer or stereoisomer. 34. A method according to claim 33 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl group; wherein said alkyl group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 35. A method according to claim 33 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkoxy group; wherein said alkoxy group has from 7 to 14 carbon atoms and is linear or branched, and substituted or unsubstituted. 36. A method according to claim 33 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with an alkyl, alkoxy, aralkyl, or aralkoxy group. 37. A method according to claim 33 wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is substituted at R.sup.1 with a nonyl group; wherein said nonyl group is linear or branched, and substituted or unsubstituted. 38. A method according to claim 33 wherein the 1,5-dideoxy-1,5-imino-D-glucitol compound, enantiomer, stereoisomer, or physiologically acceptable salt or solvate of said compound, enantiomer, or stereoisomer is administered to a human.